JP2019513770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513770A5 JP2019513770A5 JP2018553397A JP2018553397A JP2019513770A5 JP 2019513770 A5 JP2019513770 A5 JP 2019513770A5 JP 2018553397 A JP2018553397 A JP 2018553397A JP 2018553397 A JP2018553397 A JP 2018553397A JP 2019513770 A5 JP2019513770 A5 JP 2019513770A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- salt
- alkyl
- absent
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- 125000005647 linker group Chemical group 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 235000000346 sugar Nutrition 0.000 claims 4
- 150000008163 sugars Chemical class 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130754A JP7604427B2 (ja) | 2016-04-11 | 2022-08-18 | 標的核酸コンジュゲート組成物 |
| JP2024216389A JP2025031736A (ja) | 2016-04-11 | 2024-12-11 | 標的核酸コンジュゲート組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321034P | 2016-04-11 | 2016-04-11 | |
| US62/321,034 | 2016-04-11 | ||
| US201662417156P | 2016-11-03 | 2016-11-03 | |
| US62/417,156 | 2016-11-03 | ||
| US201662438310P | 2016-12-22 | 2016-12-22 | |
| US62/438,310 | 2016-12-22 | ||
| PCT/CA2017/050447 WO2017177326A1 (en) | 2016-04-11 | 2017-04-11 | Targeted nucleic acid conjugate compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130754A Division JP7604427B2 (ja) | 2016-04-11 | 2022-08-18 | 標的核酸コンジュゲート組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513770A JP2019513770A (ja) | 2019-05-30 |
| JP2019513770A5 true JP2019513770A5 (enExample) | 2020-05-21 |
Family
ID=60041316
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553397A Pending JP2019513770A (ja) | 2016-04-11 | 2017-04-11 | 標的核酸コンジュゲート組成物 |
| JP2022130754A Active JP7604427B2 (ja) | 2016-04-11 | 2022-08-18 | 標的核酸コンジュゲート組成物 |
| JP2024216389A Pending JP2025031736A (ja) | 2016-04-11 | 2024-12-11 | 標的核酸コンジュゲート組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130754A Active JP7604427B2 (ja) | 2016-04-11 | 2022-08-18 | 標的核酸コンジュゲート組成物 |
| JP2024216389A Pending JP2025031736A (ja) | 2016-04-11 | 2024-12-11 | 標的核酸コンジュゲート組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11896672B2 (enExample) |
| EP (1) | EP3443092A4 (enExample) |
| JP (3) | JP2019513770A (enExample) |
| KR (2) | KR102585288B1 (enExample) |
| CN (1) | CN109312342A (enExample) |
| AU (2) | AU2017251107B9 (enExample) |
| CA (1) | CA3020585A1 (enExample) |
| CL (1) | CL2018002892A1 (enExample) |
| IL (4) | IL318896A (enExample) |
| MA (1) | MA45478A (enExample) |
| MX (2) | MX2018012460A (enExample) |
| NZ (1) | NZ747138A (enExample) |
| SG (2) | SG11201808912QA (enExample) |
| TW (2) | TW202527991A (enExample) |
| UA (1) | UA126378C2 (enExample) |
| WO (1) | WO2017177326A1 (enExample) |
| ZA (1) | ZA201806861B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2726613T1 (sl) | 2011-06-30 | 2018-10-30 | Arrowhead Pharmaceuticals, Inc. | Sestavki in postopki za zaviranje izražanja gena virusa hepatitisa B |
| CN108271387B (zh) | 2015-08-07 | 2023-06-27 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| MX2019012280A (es) | 2017-04-11 | 2020-01-23 | Arbutus Biopharma Corp | Composiciones dirigidas. |
| TWI826492B (zh) | 2018-07-27 | 2023-12-21 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| US20220062323A1 (en) * | 2018-11-02 | 2022-03-03 | Arbutus Biopharma Corporation | Bivalent targeted conjugates |
| SG11202104461XA (en) * | 2018-11-02 | 2021-05-28 | Genevant Sciences Gmbh | Therapeutic methods |
| WO2020191183A1 (en) * | 2019-03-21 | 2020-09-24 | Mitotherapeutix Llc | Multivalent ligand clusters for targeted delivery of therapeutic agents |
| BR112022010613A2 (pt) * | 2019-12-06 | 2022-08-16 | Genevant Sciences Gmbh | Composto da fórmula, métodos de tratamento de fibrose hepática, de tratamento de esteatose hepática não alcoólica e de tratamento de esteatose hepática alcoólica, usos, método ou uso, molécula de sirna, composição e invenção |
| CN111041025B (zh) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
| EP4077473A4 (en) * | 2019-12-20 | 2024-05-01 | Arbutus Biopharma Corporation | SYNTHETIC PROCESSES AND INTERMEDIATE PRODUCTS |
| KR20230003477A (ko) | 2020-03-24 | 2023-01-06 | 제너레이션 바이오 컴퍼니 | 비-바이러스성 dna 벡터 및 인자 ix 치료제 발현을 위한 이의 용도 |
| CA3172591A1 (en) | 2020-03-24 | 2021-09-30 | Douglas Anthony KERR | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
| CN111744019B (zh) | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
| EP4331608A1 (en) * | 2020-09-30 | 2024-03-06 | Nanopeptide (Qingdao) Biotechnology Ltd. | Target ligand |
| JP2023546369A (ja) * | 2020-10-09 | 2023-11-02 | エーダーエックス ファーマシューティカルズ， インコーポレイテッド | Ｎ－アセチルガラクトサミン（ＧａｌＮＡｃ）から誘導された化合物およびオリゴヌクレオチド |
| CN116546989A (zh) * | 2020-10-09 | 2023-08-04 | 阿达尔克斯制药有限公司 | N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸 |
| IL302530A (en) * | 2020-11-06 | 2023-07-01 | Arbutus Biopharma Corp | Targeted conjugates involving modified siRNA |
| KR20240011714A (ko) | 2021-04-27 | 2024-01-26 | 제너레이션 바이오 컴퍼니 | 치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도 |
| US20240216535A1 (en) | 2021-04-27 | 2024-07-04 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| CN117836307A (zh) | 2021-06-18 | 2024-04-05 | 弘景生物科技有限公司 | 功能化的n-乙酰基半乳糖胺核苷 |
| US11692001B2 (en) | 2021-08-30 | 2023-07-04 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| WO2023045995A1 (en) * | 2021-09-23 | 2023-03-30 | Shanghai Argo Biopharmaceutical Co., Ltd. | Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents |
| AU2022361238A1 (en) * | 2021-10-05 | 2024-04-11 | Sanegene Bio Usa Inc. | Polyhydroxylated cyclopentane derivatives and methods of use |
| EP4448540A1 (en) | 2021-12-15 | 2024-10-23 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| JP2025509607A (ja) | 2022-03-14 | 2025-04-11 | ジェネレーション バイオ カンパニー | 異種プライムブーストワクチン組成物及び使用の方法 |
| US12116382B2 (en) | 2022-11-28 | 2024-10-15 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine analogs |
| CN118993970A (zh) * | 2023-05-17 | 2024-11-22 | 苏州富士莱医药股份有限公司 | 一种l96侧链化合物的制备方法 |
| GB202311334D0 (en) * | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| CN116655715B (zh) * | 2023-07-27 | 2023-10-20 | 北京炫景瑞医药科技有限公司 | 一种GalNAc衍生物、缀合物、组合物以及它们的用途 |
| CN117624266A (zh) * | 2023-10-19 | 2024-03-01 | 弘亮(上海)生物医药科技有限公司 | 一种肝靶向化合物及其寡核苷酸缀合物、偶联方法与应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833992B2 (en) * | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US9657294B2 (en) * | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US8258288B2 (en) * | 2002-02-20 | 2012-09-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) |
| WO2005026165A1 (en) | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| JP2010527618A (ja) * | 2007-05-24 | 2010-08-19 | アメリカ合衆国 | ヌクレオシドサルベージ経路を通しての核内タンパク質伝達 |
| AU2008340354B2 (en) | 2007-12-04 | 2014-04-17 | Alnylam Pharmaceuticals, Inc. | Folate-iRNA conjugates |
| AU2008340355B2 (en) * | 2007-12-04 | 2015-01-22 | Tekmira Pharmaceuticals Corporation | Targeting lipids |
| EP2291200A4 (en) * | 2008-05-22 | 2012-05-30 | Isis Pharmaceuticals Inc | PROCESS FOR MODULATING THE EXPRESSION OF RBP4 |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011056883A1 (en) * | 2009-11-03 | 2011-05-12 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr) |
| ES2562817T3 (es) * | 2010-02-24 | 2016-03-08 | Arrowhead Research Corporation | Composiciones para el suministro dirigido de ARNip |
| CA2816155C (en) | 2010-12-17 | 2020-10-27 | Arrowhead Research Corporation | Galactose cluster-pharmacokinetic modulator targeting moiety for sirna |
| US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| IN2014CN03463A (enExample) * | 2011-11-18 | 2015-10-09 | Alnylam Pharmaceuticals Inc | |
| ES2923787T5 (en) * | 2011-11-18 | 2025-12-01 | Alnylam Pharmaceuticals Inc | Modified rnai agents |
| ES2692363T3 (es) * | 2013-03-14 | 2018-12-03 | Translate Bio, Inc. | Composiciones terapéuticas de ARNm y su uso para tratar enfermedades y trastornos |
| ES2901396T3 (es) * | 2013-03-14 | 2022-03-22 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
| RU2670614C9 (ru) | 2013-05-01 | 2018-11-23 | Ионис Фармасьютикалз, Инк. | Композиции и способы модулирования экспрессии hbv и ttr |
| WO2014205451A2 (en) | 2013-06-21 | 2014-12-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| RS59986B1 (sr) * | 2013-06-27 | 2020-03-31 | Roche Innovation Ct Copenhagen As | Antisens oligomeri i konjugati koji ciljno deluju na pcsk9 |
| WO2015042564A1 (en) | 2013-09-23 | 2015-03-26 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin (ttr) associated diseases |
| ES2849600T3 (es) * | 2014-05-01 | 2021-08-19 | Ionis Pharmaceuticals Inc | Conjugados de oligonucleótidos antisentido modificados y su uso para modular la expresión de PKK |
| EP3155116A4 (en) * | 2014-06-10 | 2017-12-27 | Massachusetts Institute Of Technology | Method for gene editing |
| WO2016057693A1 (en) * | 2014-10-10 | 2016-04-14 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
| RU2017114156A (ru) * | 2014-10-10 | 2018-11-15 | Ф. Хоффманн-Ля Рош Аг | N-ацетилгалактозаминовые (galnac) фосфорамитиды, их конъюгаты с нуклеиновыми кислотами и их применение |
| JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| WO2017010575A1 (ja) | 2015-07-16 | 2017-01-19 | 協和発酵キリン株式会社 | β２ＧＰＩ遺伝子発現抑制核酸複合体 |
| EP3228326A1 (en) * | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| EP3319098A1 (en) * | 2016-11-02 | 2018-05-09 | Abiomed Europe GmbH | Intravascular blood pump comprising corrosion resistant permanent magnet |
| MX2019012280A (es) * | 2017-04-11 | 2020-01-23 | Arbutus Biopharma Corp | Composiciones dirigidas. |
| SG11202104461XA (en) * | 2018-11-02 | 2021-05-28 | Genevant Sciences Gmbh | Therapeutic methods |
| WO2020191207A1 (en) * | 2019-03-20 | 2020-09-24 | Arbutus Biopharma Corporation | Therapeutic methods for treating hepatitis b |
| EP4048801A4 (en) * | 2019-10-24 | 2023-11-22 | Genevant Sciences Gmbh | Conjugates and methods for treating acromegaly |
| BR112022010613A2 (pt) * | 2019-12-06 | 2022-08-16 | Genevant Sciences Gmbh | Composto da fórmula, métodos de tratamento de fibrose hepática, de tratamento de esteatose hepática não alcoólica e de tratamento de esteatose hepática alcoólica, usos, método ou uso, molécula de sirna, composição e invenção |
| EP4077473A4 (en) * | 2019-12-20 | 2024-05-01 | Arbutus Biopharma Corporation | SYNTHETIC PROCESSES AND INTERMEDIATE PRODUCTS |
| IL302530A (en) * | 2020-11-06 | 2023-07-01 | Arbutus Biopharma Corp | Targeted conjugates involving modified siRNA |
| EP4504269A1 (en) * | 2022-04-01 | 2025-02-12 | Genevant Sciences Gmbh | Mannose-targeted compositions |
-
0
- MA MA045478A patent/MA45478A/fr unknown
-
2017
- 2017-04-11 IL IL318896A patent/IL318896A/en unknown
- 2017-04-11 SG SG11201808912QA patent/SG11201808912QA/en unknown
- 2017-04-11 WO PCT/CA2017/050447 patent/WO2017177326A1/en not_active Ceased
- 2017-04-11 JP JP2018553397A patent/JP2019513770A/ja active Pending
- 2017-04-11 EP EP17781679.0A patent/EP3443092A4/en active Pending
- 2017-04-11 CA CA3020585A patent/CA3020585A1/en active Pending
- 2017-04-11 TW TW113135344A patent/TW202527991A/zh unknown
- 2017-04-11 NZ NZ747138A patent/NZ747138A/en unknown
- 2017-04-11 IL IL288461A patent/IL288461B2/en unknown
- 2017-04-11 UA UAA201811057A patent/UA126378C2/uk unknown
- 2017-04-11 IL IL307915A patent/IL307915B2/en unknown
- 2017-04-11 US US16/092,685 patent/US11896672B2/en active Active
- 2017-04-11 KR KR1020187032569A patent/KR102585288B1/ko active Active
- 2017-04-11 AU AU2017251107A patent/AU2017251107B9/en active Active
- 2017-04-11 CN CN201780034659.0A patent/CN109312342A/zh active Pending
- 2017-04-11 TW TW106112079A patent/TWI859114B/zh active
- 2017-04-11 KR KR1020237033350A patent/KR20230143196A/ko active Pending
- 2017-04-11 SG SG10202008301UA patent/SG10202008301UA/en unknown
- 2017-04-11 MX MX2018012460A patent/MX2018012460A/es unknown
-
2018
- 2018-10-09 IL IL262242A patent/IL262242B/en unknown
- 2018-10-10 CL CL2018002892A patent/CL2018002892A1/es unknown
- 2018-10-11 MX MX2024011712A patent/MX2024011712A/es unknown
- 2018-10-15 ZA ZA2018/06861A patent/ZA201806861B/en unknown
-
2022
- 2022-08-18 JP JP2022130754A patent/JP7604427B2/ja active Active
-
2023
- 2023-12-01 AU AU2023274208A patent/AU2023274208A1/en active Pending
-
2024
- 2024-01-10 US US18/409,330 patent/US20240245784A1/en active Pending
- 2024-09-12 US US18/883,520 patent/US20250099594A1/en active Pending
- 2024-12-11 JP JP2024216389A patent/JP2025031736A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513770A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| JP2014515406A5 (enExample) | ||
| JP2013507423A5 (enExample) | ||
| AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
| JP2016506960A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2016503799A5 (enExample) | ||
| JP2015509110A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| AR085203A1 (es) | Inhibidores benzimidazol del virus sincitial respiratorio | |
| JP2015508103A5 (enExample) | ||
| JP2012513990A5 (enExample) | ||
| JP2016534148A5 (enExample) | ||
| JP2012518029A5 (enExample) | ||
| JP2016526540A5 (enExample) | ||
| ES2613757T3 (es) | Composiciones nanoparticuladas para diagnóstico por imagen | |
| JP2009530398A5 (enExample) | ||
| JP2017511321A5 (enExample) | ||
| JP2012503621A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2012504608A5 (enExample) | ||
| JP2014515735A5 (enExample) |